Compare Harmony Gold Mining Co. (HMY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Vertex Pharmaceuticals Incorporated — how do they compare? Harmony Gold Mining Co. trades at $19.86 (market cap $12.24B), while Vertex Pharmaceuticals Incorporated trades at $529.71 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays a 2.09% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| HMY | VRTX | |
|---|---|---|
Market Cap | $12.24B | $134.25B |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $529.65 |
52-Week Low | $12.61 | $376.62 |
Enterprise Value | $12.58B | $128.37B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $19.90, up 0.96% with strong technical momentum as moving averages signal bullish alignment. The company demonstrates robust fundamentals with 2024 revenue of $61.38B and net income of $8.59B, achieving a 20.06% net margin. Recent earnings show mixed results with a Q4 2025 miss but strong operational cash flow growth to $15.65B in 2024. The stock's valuation remains reasonable with P/E of 12.26 and EV/EBITDA of 6.41, while the company transitions toward gold-copper diversification.
HMY presents a compelling value proposition with attractive profitability metrics and strategic diversification, though analyst sentiment remains cautious with 70% hold ratings. Key risks include gold price volatility and execution challenges in copper expansion. The stock trades near resistance at $20-21 with overbought RSI signals suggesting potential near-term consolidation before further upside.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
